Related Experiment Video
Updated: Jul 14, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
Characteristics and clinical course of younger patients with asymptomatic monoclonal gammopathies
Eirini Solia1, Foteini Theodorakakou1, Panagiotis Malandrakis1
1Department of Clinical Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Abstract:
Monoclonal gammopathy of undetermined significance (MGUS), smouldering multiple myeloma (SMM) and asymptomatic Waldenström's macroglobulinaemia (aWM) are precursor conditions with variable risk of progression to symptomatic malignancy. We aimed to characterize the asymptomatic monoclonal gammopathies in younger patients among 1237 consecutive patients of which 12.1% were <50 years, while 2% were <40 years. Among patients <50 years, most had MGUS and a female predominance was seen. Of patients <40 years, 71% were females, 50% had SMM and 50% MGUS. Patients <50 progressed with either SLiM criteria (clonal bone marrow plasma cell percentage ≥60% involved:uninvolved serum free light chain ratio ≥100 <1 focal lesions on MRI studies) or bone lesions detected in regular follow-up imaging, without catastrophic complications. For SMM patients <50 years, progression rate to symptomatic disease at 2, 3 and 5 years was 4%, 6% and 12% while for older patients was 9%, 13% and 20%, respectively, but adjusted for baseline risk by 20/2/20, no significant difference emerged. No patient <50 years with MGUS or aWM has yet progressed. Among SMM patients <40 years none was at high risk per 20/2/20, while no progression event occurred after a median follow-up of 3 years. In conclusion, younger patients with asymptomatic monoclonal gammopathies exhibit similar biological features compared to older patients, with generally low progression rates, suggesting early detection and low risk of complications with protocolized follow-up.
Insights
Younger patients with monoclonal gammopathies like MGUS, SMM, and aWM show similar biological traits and low progression rates compared to older adults. Protocolized follow-up suggests early detection is safe and effective.
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- Monoclonal gammopathies of undetermined significance (MGUS), smouldering multiple myeloma (SMM), and asymptomatic Waldenström's macroglobulinaemia (aWM) are precursor plasma cell disorders.
- These conditions carry a variable risk of progressing to symptomatic hematologic malignancies.
- Characterizing these precursor conditions in younger populations is crucial for understanding disease trajectories.
Purpose of the Study:
- To investigate the clinical characteristics and progression patterns of asymptomatic monoclonal gammopathies in patients under 50 and 40 years of age.
- To compare the progression rates and risk factors in younger patients versus older cohorts.
- To evaluate the safety and efficacy of protocolized follow-up in this demographic.
Main Methods:
- Retrospective analysis of 1237 consecutive patients with monoclonal gammopathies.
- Subgroup analysis of patients <50 years and <40 years, detailing MGUS, SMM, and aWM prevalence.
- Assessment of progression using SLiM criteria and bone lesion detection; comparison of SMM progression rates adjusted for baseline risk (20/2/20 criteria).
Main Results:
- Patients <50 years showed a predominance of MGUS and a female demographic; patients <40 years were 71% female, with equal SMM and MGUS prevalence.
- Progression in patients <50 years occurred via SLiM criteria or bone lesions, with lower 2, 3, and 5-year SMM progression rates (4%, 6%, 12%) compared to older patients (9%, 13%, 20%) before risk adjustment.
- No patient <50 years with MGUS or aWM progressed; no SMM patients <40 years at high risk progressed within a 3-year median follow-up.
Conclusions:
- Younger patients (<50 and <40 years) with asymptomatic monoclonal gammopathies share biological features with older patients.
- Progression rates in younger SMM patients are generally low and comparable to older patients when adjusted for risk.
- Protocolized surveillance appears safe for younger individuals with MGUS, aWM, and low-risk SMM, indicating a low risk of complications.
Related Concept Videos
Myocarditis II: Clinical Features and Diagnostic Tests
Atypical Pneumonia
Graves Disease II: Pathophysiology
Graves' Disease I: Introduction
Chronic Kidney Disease II: Clinical Manifestations
Cytomegalovirus Disease
